Biosimilar Antibodies

Cantuzumab is a monoclonal antibody that binds to CanAg, a tumor-associated antigen overexpressed in many epithelial cancers. It is commonly used as the targeting component of antibody-drug conjugates (ADCs), including Cantuzumab mertansine and Cantuzumab ravtansine, for research on targeted cytotoxic delivery and cancer therapy.

Amivantamab (FUT8-KO) is a recombinant anti-EGFR-MET monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. Functionally, Amivantamab (FUT8-KO) effectively inhibits ligand binding to EGFR and MET receptors, facilitates the endocytosis and subsequent degradation of receptor-antibody complexes, and promotes Fc-dependent cytokinesis in macrophages as well as ADCC in natural killer cells. This antibody is pivotal for research focused on the molecular mechanisms of cancer cell signaling and immune response modulation.

CMAB008 is a monoclonal antibody specifically targeting tumor necrosis factor alpha (TNFα), a cytokine involved in systemic inflammation and a key player in autoimmune disorders such as rheumatoid arthritis (RA). This antibody has therapeutic potential in modulating immune responses and alleviating symptoms associated with RA. CMAB008 represents a promising tool for both basic research and clinical applications in the study and treatment of inflammatory diseases.

The Anti-GPR73/PROKR1 Antibody is a recombinantly produced human monoclonal antibody, expressed in Chinese Hamster Ovary (CHO) cells. It specifically targets the GPR73/PROKR1 receptor, which is implicated in various physiological processes. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Teprotumumab is a human monoclonal antibody that acts as an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). This antibody specifically targets and binds to the extracellular α-subunit domain of IGF-1R, which is crucial for its ligand-binding activity. By doing so, Teprotumumab effectively blocks the receptor's interaction with its ligands, thereby inhibiting downstream signaling pathways. The antibody has been shown to impede both thyroid-stimulating hormone (TSH) and IGF-1 mediated actions in fibrocytes, leading to a reduction in TSH-dependent interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, as well as Akt phosphorylation. Teprotumumab is primarily utilized in research focused on thyroid-associated ophthalmopathy, providing a valuable tool for studying the pathophysiology and potential therapeutic interventions for this condition.

The Anti-ERBB1/EGFR/HER1 Antibody is a recombinant human monoclonal antibody produced in CHO cells, specifically targeting ERBB1/EGFR/HER1. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for studies involving the modulation and function of the ERBB1/EGFR/HER1 receptor in various cellular processes, including cell growth and differentiation.

Tagitanlimab (HBM-9167) is a humanized monoclonal antibody of the IgG1κ isotype, designed to selectively inhibit the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1. This interaction blockade is pivotal in modulating the immune system's response to tumor cells, potentially enhancing anti-tumor activity. Tagitanlimab is primarily investigated for its therapeutic potential in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), positioning it as a significant candidate for oncology research.

ABX-IL8 is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the chemokine CXCL8/IL-8. This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with a predicted molecular weight of approximately 143.94 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. ABX-IL8 is suitable for use in various immunological assays that require precise interaction with its target, making it an essential tool for research in inflammation, immune response, and related pathological conditions.

U3-1784 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting FGFR4/CD334. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human lambda (huλ) light chain, with an estimated molecular weight of 150 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended.

Gilvetmab is a caninized anti-PD-1 monoclonal antibody designed to exhibit potent inhibitory effects on the PD-1/PD-L1 interaction. By blocking this pathway, Gilvetmab effectively disrupts a critical immune checkpoint mechanism, thereby enhancing T-cell function and immune response against tumor cells. This antibody is specifically tailored for use in research related to malignant melanoma, providing a valuable tool for investigating the role of the PD-1/PD-L1 pathway in cancer immunotherapy.

Lilotomab (HH1) is a murine-derived monoclonal antibody targeting CD37, a protein predominantly expressed on the surface of B cells. This antibody has demonstrated the ability to reduce clonogenic survival, indicating its potential to inhibit the proliferation of cell colonies. Furthermore, Lilotomab exhibits significant anti-tumor activity, making it a valuable tool for research in oncology, particularly in studies focused on B-cell malignancies.

Idarucizumab is a humanized monoclonal antibody fragment designed as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, facilitating the restoration of hemostasis. This targeted mechanism of action makes Idarucizumab essential for research in anticoagulation reversal and therapeutic management.

The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DCBLD2/ESDN. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, culminating in a molecular weight of approximately 150 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended as an appropriate reference standard. This product is essential for researchers focusing on cellular signaling, vascular biology, and cancer research, providing a critical tool for elucidating the role of DCBLD2/ESDN in various biological processes.

Zanolimumab is a fully human monoclonal antibody that specifically targets CD4, a critical molecule in the T-cell receptor (TCR) signaling pathway. By binding to CD4, Zanolimumab effectively inhibits TCR signal transduction, impacting T-cell activation and function. This antibody is utilized in research focused on various immune-related conditions and cancers, including rheumatoid arthritis, psoriasis, melanoma, and both cutaneous and peripheral T-cell lymphoma. Its precise targeting makes it a valuable tool for studies aimed at understanding T-cell behavior and for developing therapeutic strategies against diseases mediated by T-cells.

PF-06342674 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the interleukin-7 receptor alpha (IL-7Ra), also known as CD127. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, with an estimated molecular weight of 145.14 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. PF-06342674 is applicable for use in various immunological assays to study the role of IL-7Ra in immune function and development.

Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody targeting L-selectin (CD62L), a cell adhesion molecule predominantly expressed on circulating neutrophils. L-selectin facilitates the migration of these cells to sites of injury via chemotaxis. Due to its mechanism of action, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma. This antibody is pivotal for research into immune response modulation and the potential therapeutic management of inflammatory conditions.

Bemarituzumab is a humanized IgG1 monoclonal antibody designed to selectively target and inhibit FGFR2b (fibroblast growth factor receptor 2b). By blocking the binding and activation of fibroblast growth factors to FGFR2b, Bemarituzumab effectively impedes cellular processes that contribute to tumor growth and proliferation. This antibody has demonstrated significant antitumor activity in clinical studies, particularly in the context of gastric and breast cancers, making it a valuable tool for research in oncology and targeted therapy development.

Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody specifically targeting Lysyl Oxidase-Like 2 (LOXL2). This antibody is utilized in the investigation of primary sclerosing cholangitis (PSC), providing a valuable tool for understanding the pathophysiological mechanisms underlying this condition.

Anti-VEGFB Antibody (CSL346) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets vascular endothelial growth factor B (VEGFB), playing a crucial role in angiogenesis and vascular development. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, resulting in a total molecular weight of approximately 145 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is suitable for a range of research applications, providing a valuable tool for studies focused on vascular biology and associated pathological conditions.

Remternetug is a human monoclonal antibody of the immunoglobulin G1-kappa class, designed to target the N3pGlu-modified peptide of amyloid beta (Aβ42), a key component in amyloid plaque formation associated with Alzheimer's disease. This antibody specifically recognizes the pyroglutamate form of Aβ, a post-translationally modified version implicated in the disease's pathology. Studies have demonstrated that Remternetug facilitates a rapid and substantial reduction in amyloid plaque deposition, making it an invaluable tool for research into the pathogenesis and potential therapeutic interventions of Alzheimer's disease.

Suciraslimab is a human IgG1 κ monoclonal antibody targeting CD22. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Codrituzumab (GC33) is a humanized monoclonal antibody that selectively targets glypican-3 (GPC3), a cell surface oncofetal protein predominantly expressed in hepatocellular carcinoma (HCC). This antibody demonstrates a high affinity for GPC3, with a dissociation constant (Kd) of 0.673 nM, indicating strong and specific binding. Codrituzumab functions by inducing antibody-dependent cellular cytotoxicity (ADCC), leading to the inhibition of tumor growth in affected cellular models. This makes it a valuable tool for research focused on cancer biology, particularly in studies investigating the mechanisms of immune response in liver cancer.

Lecankitug is a humanized monoclonal antibody engineered to selectively target and neutralize both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). By binding to these cytokines, Lecankitug effectively inhibits their signal transduction pathways, resulting in pronounced immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into the pathogenesis and potential treatment strategies for autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis.

The Anti-NGF/bNGF Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target nerve growth factor (NGF) and its precursor form, proNGF (bNGF). This antibody features a human IgG2a heavy chain and a human kappa light chain, with a predicted molecular weight of 144.14 kDa. For experimental control purposes, the Human IgG2 kappa, Isotype Control is recommended. This antibody is essential for research focused on the role of NGF in pain, inflammation, and neurodegenerative diseases, providing a valuable tool for both therapeutic and basic science investigations.

The Anti-ICAM3/CD50 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the ICAM3/CD50 antigen. This antibody features a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons and validations.

Itolizumab is a humanized recombinant monoclonal antibody specifically targeting the extracellular SRCR distal domain 1 of the CD6 antigen. This antibody effectively reduces T-cell proliferation and modulates immune response by inhibiting the production of key pro-inflammatory cytokines, including INF-γ, TNFα, and IL-6. Due to its specific action on immune modulation, Itolizumab is extensively utilized in research focused on inflammatory and autoimmune conditions such as psoriasis and rheumatoid arthritis, as well as in studies exploring therapeutic approaches for COVID-19.

Tositumomab is a murine monoclonal antibody of the IgG2a lambda isotype, specifically targeting the CD20 antigen present on both normal and malignant B lymphocytes. This antibody is designed for the precise identification and study of B-cell populations in various immunological and oncological research settings.

Ciltistotug is a monoclonal antibody that specifically targets CD40 (TNFRSF5) on human cells. Upon binding to CD40, Ciltistotug activates immune cells, thereby exerting both immunostimulatory and antitumor effects. This antibody is particularly valuable in the study of cancer immunotherapy, offering potential insights into the modulation of immune responses against tumors.

Quavonlimab (MK-1308) represents a novel monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This therapeutic agent is designed to modulate immune responses by inhibiting CTLA-4, a protein that plays a crucial role in regulating immune checkpoints. Quavonlimab is primarily utilized in research focusing on immune-oncology and the potential enhancement of anti-tumor immunity.

Baloncibart is a human monoclonal antibody of the IgG4 kappa subclass, specifically designed to target the Natriuretic Peptide Receptor A (NPR1). This antibody serves as a precise tool for the modulation and study of NPR1 receptor functions, which are crucial in various physiological processes including blood pressure regulation and fluid balance. For rigorous experimental control, it is paired with a corresponding isotype control, Human IgG4 (S228P) kappa, ensuring accurate assessment of antibody specificity and performance in research applications.

Eflapegrastim, a human IgG4 monoclonal antibody, functions as a granulocyte colony-stimulating factor (G-CSF). This biologic specifically binds to the G-CSF receptor (c-Fms), playing a crucial role in the hematopoietic system. It effectively stimulates the proliferation and differentiation of neutrophil progenitor cells, ensuring the maintenance of adequate levels of mature and functional neutrophils. Additionally, Eflapegrastim is instrumental in reducing the duration of neutropenia, thereby enhancing patient recovery and resilience in clinical settings. This makes it an essential therapeutic agent in managing conditions associated with reduced neutrophil counts, such as those experienced during chemotherapy.

Panobacumab (KBPA101) is a fully human monoclonal antibody of the IgM/κ class, produced through the immortalization of human B lymphocytes. This antibody specifically targets the lipopolysaccharide (LPS) O polysaccharide found on serotype O11 of Pseudomonas aeruginosa. Panobacumab is designed for high specificity and efficacy in recognizing this bacterial antigen, making it an invaluable tool for research into bacterial pathogenesis and immune response.

Isatuximab is a monoclonal antibody designed to specifically target CD38, a transmembrane receptor and ectoenzyme prominently expressed on the surface of cells in hematological malignancies, particularly multiple myeloma (MM). This antibody exerts its antitumor effects through a variety of biological pathways, including antibody-dependent cellular-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and the direct induction of apoptosis independently of crosslinking. Additionally, Isatuximab directly inhibits the enzymatic activity of CD38, which plays a crucial role in numerous cellular processes. This multifaceted mechanism of action makes Isatuximab a valuable tool in the research and treatment of multiple myeloma and other CD38-related disorders.

Claseprubart is a monoclonal antibody designed to specifically target and bind to human complement C1s. By binding to this key component of the complement system, Claseprubart effectively inhibits its activation, thereby exerting immunosuppressive effects. This antibody is particularly valuable in research focused on autoimmune and inflammation-related diseases, offering potential insights into the mechanisms of immune regulation and pathological inflammation.

Glofitamab (RO7082859) is a bispecific antibody designed for targeted cancer immunotherapy, featuring a unique 2:1 architecture that incorporates dual binding sites for CD20 on B cells and a single binding site for CD3 on T cells. This configuration facilitates the selective engagement and activation of T cells, which then proliferate and exert cytotoxic effects on malignant cells expressing CD20. Clinically, Glofitamab has demonstrated the capacity to induce durable complete remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), highlighting its potential as a therapeutic agent in hematologic oncology.

Denosumab is a human monoclonal antibody specifically designed to target and bind to the receptor activator of nuclear factor kappa-B ligand (RANKL) with a dissociation constant (K_D) of 0.003 nM for human RANKL. By inhibiting the interaction between RANKL and its receptor, RANK, Denosumab effectively blocks the NF-κB signaling pathway, which is crucial in the regulation of bone metabolism and immune responses. This inhibition prevents bone resorption, a key factor in various bone diseases and disorders. Additionally, Denosumab has been observed to promote proliferation and spermatogenesis. This antibody is particularly useful in research focused on bone density regulation, osteoporosis, and related bone health studies.

Tilvestamab (BGB149) is a humanized monoclonal antibody specifically targeting the AXL receptor tyrosine kinase. By effectively blocking AXL-mediated signaling pathways, Tilvestamab significantly reduces Gas6-induced AXL activation in 786-0-Luc renal cell carcinoma (RCC) cells and subsequently inhibits AKT phosphorylation. This antibody is particularly valuable in cancer research focusing on conditions characterized by overexpression of AXL, such as renal cell carcinomas.

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

The Anti-TROP-2 Antibody (Pr1E11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human TROP-2. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is ideal for research applications requiring precise TROP-2 targeting.

Rovelizumab is a humanized monoclonal antibody that targets the leukointegrin family, specifically the CD11/CD18 cell adhesion proteins. This antibody is designed for the study of various inflammatory and ischemic conditions, including multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI), and stroke. Rovelizumab's mechanism of action involves modulating leukocyte adhesion and migration, processes critical in the pathogenesis of these conditions. This makes Rovelizumab an essential tool for researchers investigating the cellular interactions and pathways underlying acute and chronic inflammatory responses.

Nerelimomab (BAYX1351) is a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). This antibody is specifically designed for use in research studies investigating the pathophysiology and potential therapeutic interventions for sepsis. By inhibiting TNF-α, Nerelimomab serves as a valuable tool for elucidating the role of this cytokine in inflammatory responses and its impact on sepsis progression.

Sabirnetug is a humanized IgG2κ monoclonal antibody specifically designed to target the Amyloid-β A4 precursor protein. This antibody is engineered for high specificity and affinity, making it an ideal tool for research focused on Alzheimer's disease and other amyloid-related disorders.

Balertatug is a human IgG1 kappa monoclonal antibody specifically targeting CD70. This antibody serves as a precise tool for the study of CD70 expression and function in various immunological contexts. For appropriate experimental control, the corresponding isotype control is Human IgG1 kappa, Isotype Control, ensuring accurate interpretation of results.

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody designed to selectively target and inhibit the programmed cell death protein 1 (PD-1). This interaction is intended to enhance the body's immune response against various cancers by blocking the PD-1 pathway, which is often exploited by tumors to evade immune detection.

HFB-200301 is a monoclonal IgG1 antibody specifically designed to target tumor necrosis factor receptor 2 (TNFR2). This antibody facilitates the activation of TNFR2, which in turn initiates the classical NF-κB signaling pathway, involving the activation of RelA and cRel-containing NF-κB dimers. This activation impacts cellular metabolism and gene expression in response to soluble TNF (sTNF). HFB-200301 holds significant potential for advancing research in cancer biology, particularly in studies exploring the molecular mechanisms of TNFR2 in tumor progression and immune responses.

Coprelotamab (GB-221) is an IgG-κ monoclonal antibody specifically designed to target EGFR2. It is produced using the CHO DG44 expression system derived from Chinese Hamster Ovary cells, ensuring high fidelity and stability in the expressed antibody. This product is pivotal for research focusing on the role of EGFR2 in various biological processes and diseases.

The Anti-CEACAM1/CD66a Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CEACAM1/CD66a antigen. This antibody features the human IgG1 heavy chain and human kappa light chain, with an estimated molecular weight of 144.98 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications requiring precise targeting of the CEACAM1/CD66a protein.